Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2284853 | 1.00 | USP2 (0.40) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL16447201 | 1.00 | USP2 (0.40) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL1287846 | 0.98 | USP2 (0.39) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL3730156 | 0.98 | USP2 (0.37) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL30361807 | 0.92 | USP2 (0.37) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL28609548 | 0.86 | USP2 (0.31) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL29198910 | 0.83 | — | — | |
| SCHEMBL5497063 | 0.80 | USP2 (0.44) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL29973085 | 0.73 | CYP2C19 (0.42) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL3345554 | 0.72 | CYP2C19 (0.58) | USP2ALDH1A1LMNACYP1A2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4267181-A1 | NUCLEIC ACID STABILIZING SOLUTION FOR VACCINES, THERAPY, DIAGNOSTICS, STORAGE, AND TRANSPORT | Daykin Molecular Systems, LLC (US) | 2023-11-01 | — | — | EP | claimed |
| US-20230225308-A1 | STABILIZING COMPOSITION AND METHOD FOR PRESERVING A BODILY FLUID | DNA GENOTEK INC. (CA) | 2023-07-20 | — | — | US | claimed |
| EP-4136427-A1 | STABILIZING COMPOSITION AND METHOD FOR PRESERVING A BODILY FLUID | DNA Genotek Inc. (CA) | 2023-02-22 | — | — | EP | claimed |
| WO-2022140038-A1 | NUCLEIC ACID STABILIZING SOLUTION FOR VACCINES, THERAPY, DIAGNOSTICS, STORAGE, AND TRANSPORT | Daykin Molecular Systems, LLC (US) | 2022-06-30 | — | — | WO | claimed |
| US-20220193229-A1 | NUCLEIC ACID STABILIZING SOLUTION FOR VACCINES, THERAPY, DIAGNOSTICS, STORAGE, AND TRANSPORT | Daykin Molecular Systems, LLC | 2022-06-23 | — | — | US | claimed |
| WO-2022003723-A1 | A METHOD FOR THE EXTRACTION OF NUCLEIC ACIDS FROM A BIOLOGICAL SAMPLE | MAGGENOME TECHNOLOGIES PVT. LTD. (IN) | 2022-01-06 | — | — | WO | claimed |
| US-11198899-B2 | Composition and method for stabilizing nucleic acids in biological samples | DNA GENOTEK INC. (CA) | 2021-12-14 | — | — | US | claimed |
| WO-2021195768-A1 | STABILIZING COMPOSITION AND METHOD FOR PRESERVING A BODILY FLUID | DNA GENOTEK INC. (CA) | 2021-10-07 | — | — | WO | claimed |
| EP-3114225-B1 | COMPOSITION AND METHOD FOR STABILIZING NUCLEIC ACIDS IN BIOLOGICAL SAMPLES | DNA GENOTEK INC (CA) | 2021-04-21 | — | — | EP | claimed |
| US-10435735-B2 | Composition and method for stabilizing nucleic acids in biological samples | DNA GENOTEK INC. (CA) | 2019-10-08 | — | — | US | claimed |
| US-7521213-B2 | Sample processing for nucleic acid amplification | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED (US) | 2009-04-21 | — | — | US | claimed |
| US-20080131876-A1 | SAMPLE PROCESSING FOR NUCLEIC ACID AMPLIFICATION | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED | 2008-06-05 | — | — | US | claimed |
| EP-1513952-A2 | COMPOSITION AND METHODS FOR OBTAINING NUCLEIC ACIDS FROM SPUTUM | DNA Genotek Inc. (CA) | 2005-03-16 | — | — | EP | claimed |
| WO-2003104251-A9 | COMPOSITION AND METHODS FOR OBTAINING NUCLEIC ACIDS FROM SPUTUM | DNA GENOTEK INC (CA) | 2004-03-11 | — | — | WO | claimed |
| WO-2003104251-A2 | COMPOSITION AND METHODS FOR OBTAINING NUCLEIC ACIDS FROM SPUTUM | DNA GENOTEK INC. (CA) | 2003-12-18 | — | — | WO | claimed |
| US-20030198598-A1 | Polypeptide derivatives | ALBERT RAINER (CH) | 2003-10-23 | — | — | US | claimed |
| US-5891656-A | DETECTING SOLUBLE, SUSPENDED, OR PARTICULATE SUBSTANCES OR ANALYTES SUCH AS PROTEINS, CARBOHYDRATES, NUCLEIC ACIDS, BACTERIA, VIRUSES, AND EUKARYOTIC CELLS AND MORE SPECIFICALLY RELATES TO COMPOSITIONS AND METHODS THAT INCLUDE LUMINESCENT | SRI INTERNATIONAL (US) | 1999-04-06 | — | — | US | claimed |
| US-5807879-A | Biotinidase-resistant biotinylated compound and methods of use thereof | UNIVERSITY OF ROCHESTER (US) | 1998-09-15 | — | — | US | claimed |
| EP-0436005-A1 | LABELED POLYPEPTIDE DERIVATIVES. | SANDOZ LTD (CH) | 1991-07-10 | — | — | EP | claimed |
| WO-1991001144-A1 | LABELED POLYPEPTIDE DERIVATIVES | SANDOZ LTD (CH) | 1991-02-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030198598-A1 | Polypeptide derivatives | HDGF, IGFBP1, VIP | USP2 3583/4885ALDH1A1 4768/4885LMNA 4029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.